MRVI News

Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you byread more...

TriLink BioTechnologies, LLC (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5...

Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

TEM stock rose as investors connected the upbeat clinical results to Tempus’s planned $1.5 billion acquisition of Personalis, announced last month.

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results...

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter financial and operating results after the market close on Thursday, August 6, 2026, and will host a conference...

TriLink BioTechnologies, LLC (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of...

TriLink, part of Maravai LifeSciences (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA...